Conferences
AAPS 2024 PHARMSCI 360
-
October 20-23, 2024
-
Salt Palace Convention Center Salt Lake City, UT
Join us October 22-25 at the Orange County Convention Center, Orlando FL for the world's premier gathering of pharmaceutical scientists.
Featured Presentation
Integrated Bioanalysis and Biotransformation Strategies for Antibody-Drug Conjugates
Li Qu, Ph.D. | Deputy Director, Non-GLP Bioanalysis, WuXi AppTec
Peng Li, Ph.D. | Senior Scientist, MetID, WuXi AppTec
This presentation will explore the comprehensive evaluation of Antibody-Drug Conjugates (ADCs) through integrated bioanalysis and advanced biotransformation studies. Key topics include nonclinical pharmacokinetic assessment, metabolite profiling, Drug-to-Antibody Ratio (DAR) analysis, and strategies to address ADC complexities throughout development. Attendees will gain insights into leveraging multiple analytical platforms and hybrid methods to overcome challenges in ADC drug development, facilitating the ADC drug R&D process.
Learning Objectives:
Understand the role of integrated bioanalysis in nonclinical pharmacokinetic evaluation of ADCs.
Learn advanced methodologies for ADC biotransformation, including metabolite profiling and DAR analysis.
Explore strategies to overcome challenges in ADC development using comprehensive analytical approaches.
Posters
Other Resources
-
Posters -
Other Resources
-
-
Development of a Rapid, High Throughput Quantitative Bioanalysis Method for Conjugated Payloads of Protease-Cleavable Antibody-Drug Conjugate (ADC) in Rat Serum Using Automated Immuno-Capture Based UPLC-MS/MS
Among the 15 ADC drugs currently on the market, there are 7 ADC drugs with protease-cleavable linkers of which 5 are MC-VC-PABC. The linker of DS-8201 is MC-GGFG which was used in many drugs‘ development. In this study, MC-VC-PABC and MC-GGFG, two protease-cleavable linkers with the highest proportion were used as examples to establish a rapid, high-throughput, sensitive, and reliable conjugated payloads quantification method, which was successfully applied to in vivo PK rat serum sample bioanalysis.
-
Comparative Metabolite Profiling and Identification of a GalNAc-Conjugated siRNA, siRNA01, in Plasma Prepared with Various Anticoagulants, Serum, and In Vivo Plasma Using LC-UV-HRMS
View More -
-
-
Comprehensive Mass Spectrometry Based Bioanalysis Strategy for Antibody-Drug Conjugate Therapeutics
PostersJan 30,2025
-
Methodologies and Strategies for ADC Biotransformation Studies
WebinarsJan 15,2025 -
Advancing Antibody-Drug Conjugates (ADCs) with Novel Payloads and Their DMPK Considerations
ArticlesDec 10,2024
-
Related Services and Platforms
-
MetID (Metabolite Profiling and Identification)Learn More -
Novel Drug Modalities DMPK Enabling PlatformsLearn More
-
In Vitro MetID (Metabolite Profiling and Identification)Learn More
-
In Vivo MetID (Metabolite Profiling and Identification)Learn More
-
Metabolite Biosynthesis and Structural CharacterizationLearn More
-
Metabolites in Safety Testing (MIST)Learn More
-
PROTAC DMPK ServicesLearn More
-
ADC DMPK ServicesLearn More
-
Oligo DMPK ServicesLearn More
-
PDC DMPK ServicesLearn More
-
Peptide DMPK ServicesLearn More
-
mRNA DMPK ServicesLearn More
-
Covalent Drugs DMPK ServicesLearn More
Stay Connected
Keep up with the latest news and insights.
